Navigation Links
Memory Pharmaceuticals Announces Six Abstracts Accepted for Presentation at Society for Neuroscience Meeting
Date:11/10/2008

MONTVALE, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced that six abstracts related to its clinical and preclinical programs have been accepted for poster presentations at the 38th Annual Meeting of the Society for Neuroscience in Washington, D.C. from November 15-19, 2008. The abstracts include additional preclinical data for R3487/MEM 3454, the Company's lead nicotinic alpha-7 receptor agonist currently in Phase 2 development for both Alzheimer's disease and cognitive impairment associated the schizophrenia (CIAS), new preclinical data for the Company's lead 5-HT(6) receptor antagonist, MEM 68626, and data from its collaboration with Amgen focused on the development of PDE10 inhibitors.

"We continue to advance the development of novel therapies for the treatment of cognitive disorders and look forward to reporting on the new data emerging from our key programs," stated David A. Lowe, Ph.D., Chief Scientific Officer of Memory Pharmaceuticals. "We and our partner Roche are evaluating R3487/MEM 3454 as a treatment for both Alzheimer's disease and CIAS, and the preclinical data for R3487/MEM 3454 adds to the growing body of evidence suggesting the compound enhances cognition. In addition, MEM 68626 continues to demonstrate efficacy in multiple models of memory, including new findings of enhanced performance in a spatial working memory task. Furthermore, we continue to progress our program focused on advancing PDE10 inhibitors for potential clinical development."

The following abstracts from Company scientists and collaborators were accepted for poster presentations at the meeting:

-- "The alpha-7 receptor partial agonist MEM 3454 increases dopamine

and acetylcholine efflux in rat medial prefrontal cortex and

hippocampus, alone and augments the effect of atypical antipsychotic

drugs"

Poster Session 874

Wednesday, November 19, 2008

1:00 p.m. - 5:00 p.m. EST

-- "Serotonin 5-HT(6) receptor antagonists modulate episodic, spatial

and working memory, highlighting a potential therapeutic role in

alleviating deficits associated with mild cognitive impairment and

Alzheimer's disease"

Poster Session 685

Tuesday, November 18, 2008

1:00 p.m. - 5:00 p.m. EST

-- "Identification and characterization of a novel small molecule

inhibitor for phosphodiesterase 10A as a potential PET-tracer using

LC-MS/MS"

Poster Session 885

Wednesday, November 19, 2008

1:00 p.m. - 5:00 p.m. EST

-- "Camk2(alpha) Heterozygous knock-out mice: a model of bipolar

disorder-related mania"

Poster Session 157

Sunday, November 16, 2008

8:00 a.m. - 12:00 p.m. EST

-- "Age and task dependent alterations in cognitive performance exist

in the rTg4510 mouse model of human tauopathy"

Poster Session 439

Monday, November 17, 2008

1:00 p.m. - 5:00 p.m. EST

-- "Behavioral characterization of rTg4510 tau transgenic mice"

Poster Session 439

Monday, November 17, 2008

1:00 p.m. - 5:00 p.m. EST

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and schizophrenia. For additional information, please visit our website at http://www.memorypharma.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or Memory Pharmaceuticals' prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the outcome of clinical trials of Memory Pharmaceuticals' drug candidates and whether they demonstrate these candidates' safety and effectiveness; the risks and uncertainties associated with: obtaining additional financing to support Memory Pharmaceuticals' R&D and clinical activities and operations; obtaining regulatory approvals to conduct clinical trials and to commercialize Memory Pharmaceuticals' drug candidates; Memory Pharmaceuticals' ability to enter into and maintain collaborations with third parties for its drug development programs; Memory Pharmaceuticals' dependence on its collaborations and its license relationships; achieving milestones under Memory Pharmaceuticals' collaborations; Memory Pharmaceuticals' dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers and consultants; protecting the intellectual property developed by or licensed to Memory Pharmaceuticals; and Memory Pharmaceuticals' ability to maintain listing on the Nasdaq Capital Market. These and other risks are described in greater detail in Memory Pharmaceuticals' filings with the Securities and Exchange Commission. Memory Pharmaceuticals may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Memory Pharmaceuticals disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.


'/>"/>
SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Memory Pharmaceuticals to Announce Third Quarter 2008 Results on Thursday, November 13, 2008
2. Leading London Neurosurgeon, Sim Farar, Partners with Los Angeles Fitness Guru to Help Baby Boomers Decrease Memory Loss
3. Alzheimers Foundation of America Offers Free Memory Screenings Nationwide
4. Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
5. Help Employees Boost Memory, Lose Weight, Get Healthier & Increase Productivity
6. Circadian Rhythm Plays Role in Memory
7. Caribou Coffee Honors Memory of One of Its Own With Amys Blend
8. Hub of fear memory formation identified in brain cells
9. Whole brain radiation increases risk of learning and memory problems in cancer patients
10. New Brain Fitness Program to Fight Memory Loss
11. Exercise May Help Prevent Age-Related Memory Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... Northern California Medical Associates ... joined their multi-specialty medical group. The dermatology practice provides general dermatologic treatment, outpatient ... to add this excellent dermatology practice to our group’s medical services,” explains NCMA ...
(Date:1/20/2017)... ... ... Aquatics Launches New ADA Portable Motion Trek BP 300 Lift. Built for durability, this pool ... it can be wheeled out of the way and stored when not in use. It ... transformed the feedback from customers into specific enhancements and created a new product that is ...
(Date:1/20/2017)... ... 2017 , ... Doctor C LLC, a company based out of Arizona that ... continue the marketing and distribution of its product, The Right C. , The Right ... absorption than traditional vitamin C supplements. At the trade show, Doctor C had the ...
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, 2017 , ... ... highest level of nutritional and bodybuilding supplements, announced it attended the January ECRM trade ... a respected bodybuilder and nutritional scientist who was determined to create a line of ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is Greater than Sin”: ... who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the ... an educator interacting with countless women who had little knowledge of the female characters ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... Jan. 20, 2017  Palladian Health, a leading ... the launch of an opioid management program which ... opioids and helps stem the growing tide of ... to treat chronic non-cancer pain (back pain, neck ... and lack of evidence regarding long-term effectiveness. ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 ... USD 233.7 billion by 2025, according to a ... market is anticipated to be predominantly driven by ... resulting into the large-scale production of new and ... the influx of drugs at an unprecedented rate ...
(Date:1/19/2017)... Jan. 19, 2017 Report Details ... Alzheimer,s ... Leading Companies – our new study reveals trends, R&D ... and events affecting the Alzheimer,s disease therapeutics and diagnostics ... these key questions: - How is the Alzheimer,s disease ...
Breaking Medicine Technology: